Home › Liver Cancer › Florida › Tampa
Liver Cancer clinical trials in Tampa, FL
3 studies for Liver Cancer are looking for participants at sites in and around Tampa (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
RecruitingPhase 1/2
- Moffitt Cancer Center - International Plaza, Tampa
- Moffitt Cancer Center - McKinley Campus, Tampa
- Moffitt Cancer Center, Tampa
- and 1 more
Multi-analyte Blood Test Clinical Trial
RecruitingObservational study
- Guardian Angel Research Center, Tampa
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Tampa
About Liver Cancer
The most common form of liver cancer in adults is hepatocellular carcinoma. Learn about diagnosis, treatment and taking part in research studies.
More about Liver Cancer on MedlinePlus
Liver Cancer trials in other cities
- Houston, TX14 studies
- Los Angeles, CA11 studies
- Cleveland, OH11 studies
- Dallas, TX10 studies
- Boston, MA9 studies
- Chicago, IL8 studies
- St. Louis, MO8 studies
- Philadelphia, PA7 studies
- Durham, NC7 studies
- San Francisco, CA6 studies
- New York City, NY6 studies
- Washington, DC6 studies
Other studies in Tampa
- Non-Small Cell Lung Cancer51 studies
- Breast Cancer43 studies
- Cancer (all types)39 studies
- Colorectal Cancer34 studies
- Acute Myeloid Leukemia29 studies
- Metastatic Cancer29 studies
- Lung Cancer29 studies
- Pancreatic Cancer26 studies
- Ovarian Cancer21 studies
- Melanoma19 studies
- Myelodysplastic Syndromes19 studies
- Prostate Cancer18 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.